|
rs17174393
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121913500
|
|
|
0.050 |
GeneticVariation |
BEFREE |
En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody.
|
27153165 |
2017 |
|
rs121913500
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In malignant glioma the presence of the IDH1 mutation (IDH1(R132H)) is associated with better clinical outcome.
|
26328938 |
2015 |
|
rs121913500
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas.
|
24929863 |
2014 |
|
rs121913500
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma.
|
23619925 |
2013 |
|
rs121913500
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
|
29039591 |
2017 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
|
29039591 |
2017 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
|
27799506 |
2016 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
|
27799506 |
2016 |
|
rs1920116
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A recent genome-wide association study has identified an association between rs1920116 near TERC and high-grade glioma in populations of European ancestry.
|
26017031 |
2015 |
|
rs1920116
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Here we identify a new SNP associated with glioma risk, rs1920116 (near TERC), that reached genome-wide significance (Pcombined = 8.3 × 10(-9)) in a meta-analysis of genome-wide association studies (GWAS) of high-grade glioma and replication data (1,644 cases and 7,736 controls).
|
24908248 |
2014 |
|
rs1057519902
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation.
|
31139567 |
2019 |
|
rs117677079
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs117677079 polymorphism was strongly associated with an increased risk of glioma (OR 1.64, p = 0.003) and a worse prognosis for glioma, especially in high-grade glioma (HR 1.76, p = 0.005).
|
30536196 |
2019 |
|
rs1553260624
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation.
|
31139567 |
2019 |
|
rs2239647
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs2239647 polymorphism was strongly associated with an increased risk of glioma (OR = 1.90, p = 0.007) and a worse prognosis for glioma, especially in high-grade glioma (HR = 1.67, p = 0.034).
|
31759389 |
2019 |
|
rs1057519903
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.
|
29264735 |
2018 |
|
rs1057519904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.
|
29264735 |
2018 |
|
rs12917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Logistic regression analysis showed that Leu</span>84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas.
|
28409559 |
2017 |
|
rs1424913115
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Logistic regression analysis showed that Leu</span>84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas.
|
28409559 |
2017 |
|
rs2308321
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study aims to investigate the associations of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) resistance and prognosis of patients with malignant gliomas.
|
28409559 |
2017 |
|
rs2252586
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Similarly, stratified analysis of rs2252586 by stages revealed the similar trend, with OR of 1.26 (95 %CI = 1.17-1.35) in high-grade glioma and OR of 1.15 (95 %CI = 1.08-1.22) in low-grade glioma.
|
26243184 |
2016 |
|
rs7502563
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analyses indicated that the association between rs7502563 and glioma was more pronounced in females (OR = 0.40, 95 % CI = 0.20-0.80, P = 0.0091), older subjects (OR = 0.47, 95 % CI = 0.26-0.86, P = 0.0135), and subjects with high-grade glioma (OR = 0.45, 95 % CI = 0.27-0.77, P = 0.0031).
|
26361958 |
2016 |